



**Subject:** Cervical Cancer (HPV) Vaccine\*

**Effective Date:** July 25, 2006

**Department(s):** Utilization Management

---

**Policy:** Quadrivalent and bivalent human papilloma virus (HPV) vaccines are reimbursable under Plans administered by QualCare, Inc., under the circumstances specified in this policy.

**Objective:** To assure proper and consistent reimbursement and to define the population for which HPV vaccines are reimbursable.

**Procedure:**

1. Quadrivalent, bivalent and nonavalent HPV vaccines are covered as part of the immunizations in each Plan's wellness policies.
2. The **CPT codes** for these vaccines are:
  - a. **90649** (quadrivalent)
  - b. **90650** (bivalent)
  - c. **90651**(nonavalent)
3. Quadrivalent, bivalent and nonavalent HPV vaccines, which are administered as a series of three injections, are covered for males and females from age 9 years through age 26 years.
4. If the three-injection series is begun before the individual's 27<sup>th</sup> birthday, the remaining injections in the series are reimbursable even if they continue past the 27<sup>th</sup> birthday.

## References

Petrosky E, Bocchini JA, Hariri S, Chesson H, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. *MMWR* 2015; 64(11):300-304(Mar)

Giuliano AR, Palefsky JM, Goldstone S, Moreira Jr. ED, et. al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. *N Eng J Med*. 2011;364(5):401-11(Feb)

Centers for Disease Control and Prevention. Recommendations on the use of Quadrivalent Human Papillomavirus Vaccine in Males-Advisory Committee on Immunization Practices (ACIP). *MMWR* 2011;60(50):1705-8(Dec)

US Food and Drug Administration. FDA Approves New Indication for Gardasil to Prevent Genital Warts in Men and Boys. *FDA News Release* 10/16/09 available at <http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2009/ucm187003.htm> accessed 03/27/10

Brown DR, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. *J Infect Dis* 2009;199(7):926-935 (Apr. 1)

Wheeler CM, Kjaer SK, Sigurdsson K, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. *J Infect Dis* 2009; 199(7):936-944 (Apr 1)

Schwarz TF, Spaczynski M, Schneider A, et al. Immunogenicity and tolerability of an HPV-16/18 AS04-adjuvanted prophylactic cervical cancer vaccine in women aged 15-55 years. *Vaccine* 2009; 27(4):581-7 (Jan 22)

Petäjä T, Keränen H, Karppa T, et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. *J Adolesc Health* 2009;44(1):33-40 (Jan)

Dooren JC. Ill Effects Likely Not Tied to Gardasil, Study Says. *Wall Street Journal* 10/23/08 p B9

Moscicki A-B. HPV Vaccines: Today and in the Future. *J Adolesc Health* 2008;43(4):S26-S40 (Oct)

Infectious Diseases Society of America. ACIP Makes New Recommendations on Rabies, HPV, Pneumococcal Vaccines. *IDSA News*2008;18(7) (Jul)

Haupt RM. GARDASIL<sup>®</sup> Update: End-of-Study (16-26 year-olds) Adult Women (24-45 year-olds). Report to ACIP. February 27, 2008

Hayes, Inc. Hayes Medical Technology Directory. *Human Papillomavirus Vaccines for Prevention of Cervical Cancer*. Lansdale, PA: Hayes, Inc. September 25, 2006

Bonney LE, Lally M, Williams DR et al Where to begin human papillomavirus vaccination? *Lancet Infect Dis* 2006;6(7):389-390 (Jul)

Merck & Co., Inc. GARDASIL [Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine]. Prescribing Information 9682300. June 2006 at [www.gardasil.com](http://www.gardasil.com) accessed 6/9/06

US Food and Drug Administration, Office of Women's Health. HPV (human papillomavirus). *Take Time to Care*. June 2006

---FDA Licenses New Vaccine for Prevention of Cervical Cancer and Other Disease in Females Caused by Human Papillomavirus. *FDA News* 2006;P06-77 (Jun 8)

Spisek R, Dhodapkar MV. Immunoprevention of Cancer. *Hem/Onc Clin N Amer* 2006;20(3):735-750 (Jun)

Partridge JM, Koutsky LA. Genital human papillomavirus infection in men. *Lancet Infect Dis* 2006;6(1):21-31 (Jan)

---Who should be vaccinated against human papillomavirus? *Lancet Infect Dis* 2006;6(1):1 (Jan)

Stanberry LR, Rosenthal SL. Progress in Vaccines for Sexually Transmitted diseases. *Infect Dis Clin N Amer* 2005;19(2):477-490 (Jun)

Villa LL, Costa RL, Petta CA *et al*. Prophylactic quadrivalent human papillomavirus (types 6, 11,16, and 18) L1 virus-like particle vaccine in young women : A randomised double-blind placebo-controlled multicentre phase II efficacy trial. *Lancet Oncol* 2005;6(5):271-278 (May)

American College of Obstetricians and Gynecologists. 2005. Human Papillomavirus. ACOG Practice Bulletin No. 61. (Apr)

Koutsky LA, Ault KA, Wheeler CM, *et al*. A controlled trial of a human papillomavirus type 16 vaccine. *N Eng J Med* 2002;372(21):1645-1651

Drafted By/Date: B. Fisher, MD 07/10/06  
Approved By/Date: QM Committee 07/25/06  
Revised By/Date: BFisher, MD 10/29/08  
Approved By/Date: QM Committee 12/09/08  
Revised By/date: BFisher, MD 03/27/10  
Approved By/Date: QM Committee 04/27/10  
Reviewed without revision By/Date: MMcNeil, MD 03/12/12  
Approved By/Date: QM Committee 3/27/12  
Reviewed w/o Revision By/Date: MMcNeil, MD 04/30/14  
Approved By/Date: QM Committee 5/13/14  
Revised By/Date: MMcNeil, MD 05/28/15  
Approved By/Date: QM Committee 7/28/15

\*Consistent with Summary Plan Description (SPD). When there is discordance between this policy and the SPD, the provisions of the SPD prevail.